Left Ventricular Hypertrophy in CKD Patients (NCT07380893) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Left Ventricular Hypertrophy in CKD Patients
100 participantsStarted 2026-01-15
Plain-language summary
The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.
The main question it aims to answer is:
Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults (≥18 years) diagnosed with CKD stages 3-5.
* Stable clinical condition for ≥3 months.
* Anemia (Hb \<10 g/dL) for cohort phase.
* Willingness to participate and provide informed consent.
Exclusion Criteria:
* Valvular or ischemic heart disease.
* Uncontrolled hypertension (BP \>180/110 mmHg).
* Acute coronary syndrome or decompensated heart failure in the past 3 months.
* Malignancy or active infection
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in LVMI following erythropoietin therapy in anemic CKD patients.
Timeframe: - baseline transthoracic echocardiography will be performed for all group study.